Open Access

SGLT2 Inhibitors as a Central Cardio-Renal-Metabolic Therapy: The Modern Day ACE Inhibitor.

Topic: Chronic Heart Failure
Organised by CHANGE IME supported by an unrestricted educational grant from AstraZeneca

Presentation

About the speaker

Doctor Muthiah Vaduganathan

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
8 presentations
0 follower

2 more presentations in this session

Heart failure in context.

Speaker: Professor C. Linde (Stockholm, SE)

Thumbnail

Treating the whole spectrum of heart failure.

Speaker: Professor G. Rosano (London, GB)

Thumbnail

Access the full session

SGLT2 inhibitors and heart failure in the cardiorenal spectrum

Speakers: Doctor M. Vaduganathan, Professor C. Linde, Professor G. Rosano
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ACVC Premium Access

TTM2: a game changer?

18 March 2022

ACVC Premium Access

Time is kidney: relation between pain-to-balloon time and acute kidney injury among ST segment elevation myocardial infarction patients undergoing primary percutaneous intervention

18 March 2022

Open Access

Conclusion.

23 October 2021

This platform is supported by

logo Novo Nordisk